Premium
Changes in serum erythropoietin and the reticulocyte count during chemotherapy for leukemias
Author(s) -
Sawabe Y.,
Kikuno K.,
Iseki T.,
Iida S.,
Tabata Y.,
Yonemitsu H.
Publication year - 1996
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1996.tb01397.x
Subject(s) - reticulocyte , medicine , erythropoietin , chemotherapy , aplastic anemia , regimen , anemia , leukemia , hemoglobin , gastroenterology , immunology , bone marrow , biology , biochemistry , messenger rna , gene
We serially determined serum erythropoietin (Epo) and the reticulocyte count in patients with various types of leukemia during chemotherapy. Serum Epo increased soon after the initiation of chemotherapy and decreased after the termination of therapy irrespective of the types of leukemia or treatment regimen. However, it did not stay at low level but fluctuated. The reticulocyte count, on the other hand, showed a transient rise while serum Epo level descended. The value of serum Epo when increased was higher than the value expected from hemoglobin concentration; this finding was similar to that in aplastic anemia. These results suggest that myelosuppression is a major factor for the increase in serum Epo level during leukemia chemotherapy.